Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” Lechleiter Says At JP Morgan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan. Though the project is high risk, Lechleiter pointed to the company’s full pipeline and success of diabetes portfolio as signs of Lilly’s momentum.